Difference between revisions of "CH Basel Uteng M"
From Bioblast
| Line 7: | Line 7: | ||
|Team previous=Dong Min | |Team previous=Dong Min | ||
|Status=O2k 2006- | |Status=O2k 2006- | ||
|info=[ | |info=[[MiPNet12.14 IOC39|IOC39]], [[MiPNet11.06 IOC36|IOC36]] | ||
}} | }} | ||
* Previously CH_Muttenz_Dong M | * Previously CH_Muttenz_Dong M | ||
Revision as of 08:55, 14 June 2016
CH Basel Uteng M
| O2k-Network Lab | Novartis Pharma AG, Werk Klybeck |
|---|---|
| Address | , 4002 |
| City | Basel |
| State/Prov | |
| Country | Switzerland |
| Weblink | |
| Contact | |
| Team | Riebel Virginie |
| Team previous | Dong Min |
| Status | O2k 2006- |
| Oroboros Events | IOC39, IOC36 |
| Topics |
O2k-Publications
| Published | Reference | |
|---|---|---|
| Brecht 2016 Toxicol In Vitro | 2016 | Brecht K, Riebel V, Couttet P, Paech F, Wolf A, Chibout SD, Pognan F, Krähenbühl S, Uteng M (2016) Mechanistic insights into selective killing of OXPHOS-dependent cancer cells by arctigenin. Toxicol In Vitro 40:55-65. |
O2k-Abstracts
update please
- Previously CH_Muttenz_Dong M
